Irritable Bowel Syndrome: Modern Concepts and Management Options

American Journal of Medicine

Volumn 128, Issue 8, 2015, Pages 817-827

  Sayuk, Gregory S ^a,b   Gyawali, C Prakash ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Division of Gastroenterology   (United States)

Author keywords

Diagnosis; Irritable bowel; Pathophysiology; Treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; LAXATIVE; PROBIOTIC AGENT;

ABDOMINAL PAIN; ALTERNATIVE MEDICINE; BACTERIAL OVERGROWTH; BEHAVIOR THERAPY; BLOOD CELL COUNT; CLINICAL FEATURE; COGNITIVE THERAPY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED PRACTICE; HUMAN; INTESTINE FUNCTION; IRRITABLE COLON; OCCULT BLOOD; PATHOGENESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; CONSTIPATION; COST OF ILLNESS; DIARRHEA; IRRITABLE BOWEL SYNDROME; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ABDOMINAL PAIN; CONSTIPATION; COST OF ILLNESS; DIARRHEA; HUMANS; IRRITABLE BOWEL SYNDROME; TREATMENT OUTCOME;

EID: 84937812526     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.01.036     Document Type: Review

References (128)

1. D.A. Drossman, E. Corazziari, M. Delvaux, and et al. Rome III: The Functional Gastrointestinal Disorders 2006 Degnon Associates, Inc McLean
2. G.F. Longstreth, W.G. Thompson, W.D. Chey, and et al. Functional bowel disorders Gastroenterology 130 2006 1480 1491
3. D.A. Drossman, Z. Li, E. Andruzzi, and et al. U.S. Householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact Dig Dis Sci 38 1993 1569 1580
4. H.B. El-Serag Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life Rev Gastroenterol Disord 3 Suppl 2 2003 S3 S11
5. A. Hungin, L. Chang, G. Locke, and et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact Aliment Pharmacol Ther 21 2005 1365 1375
6. G.F. Longstreth, and G. Wolde-Tsadik Irritable bowel-type symptoms in HMO examinees. Prevalence, demographics, and clinical correlates Dig Dis Sci 38 1993 1581 1589
7. I.M. Gralnek, R.D. Hays, A. Kilbourne, and et al. The impact of irritable bowel syndrome on health-related quality of life Gastroenterology 119 2000 654 660
8. K.W. Wyrwich, H.S. Nelson, W.M. Tierney, and et al. Clinically important differences in health-related quality of life for patients with asthma: an expert consensus panel report Ann Allergy Asthma Immunol 91 2003 148 153
9. Z.M. Younossi, N. Boparai, L.L. Price, and et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease Am J Gastroenterol 96 2001 2199 2205
10. G.F. Longstreth, A. Wilson, K. Knight, and et al. Irritable bowel syndrome, health care use, and costs: a U.S. Managed care perspective Am J Gastroenterol 98 2003 600 607
11. K.A. Nyrop, O.S. Palsson, R.L. Levy, and et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain Aliment Pharmacol Ther 26 2007 237 248
12. D.A. Drossman, M. Camilleri, E.A. Mayer, and W.E. Whitehead AGA technical review on irritable bowel syndrome Gastroenterology 123 2002 2108 2131
13. A.P. Manning, W.G. Thompson, K.W. Heaton, and A.F. Morris Towards positive diagnosis of the irritable bowel Br Med J 2 1978 653 654
14. A.C. Ford, P. Bercik, D.G. Morgan, and et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care Gastroenterology 145 2013 1262 1270 e1
15. P. Jellema, D.A. van der Windt, F.G. Schellevis, and H.E. van der Horst Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care Aliment Pharmacol Ther 30 2009 695 706
16. W.E. Whitehead, O.S. Palsson, A.D. Feld, and et al. Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome Aliment Pharmacol Ther 24 2006 137 146
17. S.J. Vanner, W.T. Depew, W.G. Paterson, and et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome Am J Gastroenterol 94 1999 2912 2917
18. W. Kruis, C. Thieme, M. Weinzierl, and et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease Gastroenterology 87 1984 1 7
19. G.S. Sayuk, J.E. Elwing, P.J. Lustman, and R.E. Clouse High somatic symptom burdens and functional gastrointestinal disorders Clin Gastroenterol Hepatol 5 2007 556 562
20. W.E. Whitehead, O.S. Palsson, R.R. Levy, and et al. Comorbidity in irritable bowel syndrome Am J Gastroenterol 102 2007 2767 2776
21. W.H. Brown, W.D. Chey, and G.H. Elta Number of responses on a review of systems questionnaire predicts the diagnosis of functional gastrointestinal disorders J Clin Gastroenterol 36 2003 222 227
22. L. Ohman, and M. Simren Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions Nat Rev Gastroenterol Hepatol 7 2010 163 173
23. E.A. Mayer, B.D. Naliboff, and A.D. Craig Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders Gastroenterology 131 2006 1925 1942
24. U. Ladabaum, S. Minoshima, and C. Owyang Pathobiology of visceral pain: molecular mechanisms and therapeutic implications V. Central nervous system processing of somatic and visceral sensory signals Am J Physiol Gastrointest Liver Physiol 279 2000 G1 G6
25. W.L. Hasler Traditional thoughts on the pathophysiology of irritable bowel syndrome Gastroenterol Clin North Am 40 2011 21 43
26. L. Chang, E.A. Mayer, T. Johnson, and et al. Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia Pain 84 2000 297 307
27. J.S. Leeds, A.D. Hopper, R. Sidhu, and et al. Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency Clin Gastroenterol Hepatol 8 2010 433 438
28. M.E. Money, and M. Camilleri Review: management of postprandial diarrhea syndrome Am J Med 125 2012 538 544
29. M. Simadibrata, R.J. Wanders, G. Jan, and et al. Examination of small bowel enzymes in chronic diarrhea J Gastroenterol Hepatol 18 2003 53 56
30. J.R. Walters Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder Expert Rev Gastroenterol Hepatol 4 2010 561 567
31. A. Bajor, H. Tornblom, M. Rudling, and et al. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS Gut 64 2015 84 92
32. A. Deiteren, M. Camilleri, A.E. Bharucha, and et al. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions Neurogastroenterol Motil 22 2010 415 423 e95
33. A. Deiteren, M. Camilleri, D. Burton, and et al. Effect of meal ingestion on ileocolonic and colonic transit in health and irritable bowel syndrome Dig Dis Sci 55 2010 384 391
34. M.D. Gershon, and J. Tack The serotonin signaling system: from basic understanding to drug development for functional GI disorders Gastroenterology 132 2007 397 414
35. M. Simren, G. Barbara, H.J. Flint, and et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report Gut 62 2013 159 176
36. L. Ohman, and M. Simren Intestinal microbiota and its role in irritable bowel syndrome (IBS) Curr Gastroenterol Rep 15 2013 323
37. I. Posserud, P.O. Stotzer, E.S. Bjornsson, and et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome Gut 56 2007 802 808
38. I.B. Jeffery, P.W. O'Toole, L. Ohman, and et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota Gut 61 2012 997 1006
39. R. Spiller, and K. Garsed Postinfectious irritable bowel syndrome Gastroenterology 136 2009 1979 1988
40. M. Grover, M. Camilleri, K. Smith, and et al. On the fiftieth anniversary postinfectious irritable bowel syndrome: mechanisms related to pathogens Neurogastroenterol Motil 26 2014 156 167
41. K.A. Gwee, Y.L. Leong, C. Graham, and et al. The role of psychological and biological factors in postinfective gut dysfunction Gut 44 1999 400 406
42. H.L. Nielsen, J. Engberg, T. Ejlertsen, and H. Nielsen Psychometric scores and persistence of irritable bowel after Campylobacter concisus infection Scand J Gastroenterol 49 2014 545 551
43. J.S. Labus, B.D. Naliboff, S.M. Berman, and et al. Brain networks underlying perceptual habituation to repeated aversive visceral stimuli in patients with irritable bowel syndrome Neuroimage 47 2009 952 960
44. M.B. Larsson, K. Tillisch, A.D. Craig, and et al. Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome Gastroenterology 142 2012 463 472 e3
45. E.A. Mayer, Q. Aziz, S. Coen, and et al. Brain imaging approaches to the study of functional GI disorders: a Rome working team report Neurogastroenterol Motil 21 2009 579 596
46. L. Bohn, S. Storsrud, H. Tornblom, and et al. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life Am J Gastroenterol 108 2013 634 641
47. J. Yang, M. Fox, Y. Cong, and et al. Lactose intolerance in irritable bowel syndrome patients with diarrhoea: the roles of anxiety, activation of the innate mucosal immune system and visceral sensitivity Aliment Pharmacol Ther 39 2014 302 311
48. W. Marcason What is the FODMAP diet? J Acad Nutr Diet 112 2012 1696
49. J.G. Muir, and P.R. Gibson The low FODMAP diet For treatment of irritable bowel syndrome and other gastrointestinal disorders Gastroenterol Hepatol 9 2013 450 452
50. H.M. Staudacher, P.M. Irving, M.C. Lomer, and K. Whelan Mechanisms and efficacy of dietary FODMAP restriction in IBS Nat Rev Gastroenterol Hepatol 11 2014 256 266
51. C.C. Ferch, and W.D. Chey Irritable bowel syndrome and gluten sensitivity without celiac disease: separating the wheat from the chaff Gastroenterology 142 2012 664 666
52. M.I. Vazquez-Roque, M. Camilleri, T. Smyrk, and et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function Gastroenterology 144 2013 903 911 e3
53. G.S. Sayuk, J.E. Elwing, P.J. Lustman, and R.E. Clouse Predictors of premature antidepressant discontinuation in functional gastrointestinal disorders Psychosom Med 69 2007 173 181
54. C.S. North, B.A. Hong, and D.H. Alpers Relationship of functional gastrointestinal disorders and psychiatric disorders: implications for treatment World J Gastroenterol 13 2007 2020 2027
55. B.M. Spiegel, I.M. Gralnek, R. Bolus, and et al. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome Arch Intern Med 164 2004 1773 1780
56. Y.A. Saito, and N.J. Talley Genetics of irritable bowel syndrome Am J Gastroenterol 103 2008 2100 2104 quiz 2105
57. Y.A. Saito, J.M. Zimmerman, W.S. Harmsen, and et al. Irritable bowel syndrome aggregates strongly in families: a family-based case-control study Neurogastroenterol Motil 20 2008 790 797
58. M. Camilleri, and D.A. Katzka Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome Am J Physiol Gastrointest Liver Physiol 302 2012 G1075 G1084
59. W.E. Ek, A. Reznichenko, S. Ripke, and et al. Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts Gut 2014 [Epub ahead of print]
60. K. Bradford, W. Shih, E.J. Videlock, and et al. Association between early adverse life events and irritable bowel syndrome Clin Gastroenterol Hepatol 10 2012 385 390 e1-e3
61. L. Chang The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome Gastroenterology 140 2011 761 765
62. A.C. Ford, N.J. Talley, S.J. Veldhuyzen van Zanten, and et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA 300 2008 1793 1805
63. A.C. Ford, W.D. Chey, N.J. Talley, and et al. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis Arch Intern Med 169 2009 651 658
64. B.M. Spiegel, V.P. DeRosa, I.M. Gralnek, and et al. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis Gastroenterology 126 2004 1721 1732
65. A.C. Ford, B.M. Spiegel, N.J. Talley, and P. Moayyedi Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis Clin Gastroenterol Hepatol 7 2009 1279 1286
66. A.L. Fumi, and K. Trexler Rifaximin treatment for symptoms of irritable bowel syndrome Ann Pharmacother 42 2008 408 412
67. American College of Gastroenterology Task Force on Irritable Bowel, L.J. Brandt, W.D. Chey, A.E. Foxx-Orenstein, and et al. An evidence-based position statement on the management of irritable bowel syndrome Am J Gastroenterol 104 Suppl 1 2009 S1 S35
68. R. Spiller, Q. Aziz, F. Creed, and et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management Gut 56 2007 1770 1798
69. W.D. Chey, B. Nojkov, J.H. Rubenstein, and et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial Am J Gastroenterol 105 2010 859 865
70. D.A. Drossman, L. Chang, N. Bellamy, and et al. Severity in irritable bowel syndrome: a Rome Foundation Working Team report Am J Gastroenterol 106 2011 1749 1759 quiz 1760
71. L. Ruepert, A.O. Quartero, N.J. de Wit, and et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome Cochrane Database Syst Rev 8 2011 CD003460
72. P. Moayyedi, E.M. Quigley, B.E. Lacy, and et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis Am J Gastroenterol 109 2014 1367 1374
73. J. Shearer, and A.C. Ford Polyethylene glycol in constipation-predominant irritable bowel syndrome Am J Gastroenterol 109 2014 135
74. R.W. Chapman, V. Stanghellini, M. Geraint, and M. Halphen Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome Am J Gastroenterol 108 2013 1508 1515
75. S. Patel, D. Berrada, and A. Lembo Review of tegaserod in the treatment of irritable bowel syndrome Expert Opin Pharmacother 5 2004 2369 2379
76. Zelmac (tegaserod) Advisory Committee Briefing Document. Available at: www.fda.gov/ohrms/dockets/ac/00/backgrd/3627b1a.pdf. Accessed February 3, 2014.
77. E.M. Quigley Prucalopride: safety, efficacy and potential applications Therap Adv Gastroenterol 5 2012 23 30
78. D.A. Drossman, W.D. Chey, J.F. Johanson, and et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies Aliment Pharmacol Ther 29 2009 329 341
79. Amitiza Prescribing Information. Available at: www.amitiza.com. Accessed February 4, 2014.
80. R.W. Busby, M.M. Kessler, W.P. Bartolini, and et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation J Pharmacol Exp Ther 344 2013 196 206
81. M.I. Vazquez-Roque, and E.P. Bouras Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome Adv Ther 30 2013 203 211
82. W.D. Chey, A.J. Lembo, B.J. Lavins, and et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety Am J Gastroenterol 107 2012 1702 1712
83. S. Rao, A.J. Lembo, S.J. Shiff, and et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation Am J Gastroenterol 107 2012 1714 1724 quiz 1725
84. J. Castro, A.M. Harrington, P.A. Hughes, and et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′,5′-monophosphate Gastroenterology 145 2013 1334 1346 e1-e11
85. D.K. Atluri, A.K. Chandar, A.E. Bharucha, and Y. Falck-Ytter Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis Neurogastroenterol Motil 26 2014 499 509
86. P.S. Efskind, T. Bernklev, and M.H. Vatn A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome Scand J Gastroenterol 31 1996 463 468
87. S.B. Hanauer The role of loperamide in gastrointestinal disorders Rev Gastroenterol Disord 8 2008 15 20
88. E. Corazziari Role of opioid ligands in the irritable bowel syndrome Can J Gastroenterol 13 Suppl A 1999 71A 75A
89. M. Camilleri Advances in understanding of bile acid diarrhea Expert Rev Gastroenterol Hepatol 8 2014 49 61
90. B.S. Wong, M. Camilleri, P. Carlson, and et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea Clin Gastroenterol Hepatol 10 2012 1009 1015 e3
91. A.N. Barkun, J. Love, M. Gould, and et al. Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment Can J Gastroenterol 27 2013 653 659
92. R.J. Saad Peripherally acting therapies for the treatment of irritable bowel syndrome Gastroenterol Clin North Am 40 2011 163 182
93. A. Nakai, M. Diksic, Y. Kumakura, and et al. The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome Neurogastroenterol Motil 17 2005 212 221
94. A.J. Lembo, K.W. Olden, V.Z. Ameen, and et al. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials Clin Gastroenterol Hepatol 2 2004 675 682
95. E.A. Mayer, S. Berman, S.W. Derbyshire, and et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients Aliment Pharmacol Ther 16 2002 1357 1366
96. T. Lembo, R.A. Wright, B. Bagby, and et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome Am J Gastroenterol 96 2001 2662 2670
97. V. Andresen, and S. Hollerbach Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? Drug Saf 27 2004 283 292
98. J.H. Lewis Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective Exp Rev Gastroenterol Hepatol 4 2010 13 29
99. B. Shen, and E.E. Soffer Alosetron (Lotronex) is back: should I use it to treat my patients with irritable bowel syndrome? Cleve Clin J Med 70 2003 64 65
100. L. Wedlake, R. A'Hern, D. Russell, and et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome Aliment Pharmacol Ther 30 2009 707 717
101. R.E. Clouse, C. Prakash, and R.J. Anderson Antidepressants for functional gastrointestinal symptoms and syndromes: a meta-analysis Gastroenterology 120 suppl 1 2001 A642
102. R.E. Clouse Antidepressants for irritable bowel syndrome Gut 52 2003 598 599
103. V. Morgan, D. Pickens, S. Gautam, and et al. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome Gut 54 2005 601 607
104. A.C. Ford, E.M. Quigley, B.E. Lacy, and et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis Am J Gastroenterol 109 2014 1350 1365 quiz 1366
105. A.C. Ford, N.J. Talley, P.S. Schoenfeld, and et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis Gut 58 2009 367 378
106. M. Grover, and M. Camilleri Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases J Gastroenterol 48 2013 177 181
107. S.B. Menees, M. Maneerattannaporn, H.M. Kim, and W.D. Chey The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis Am J Gastroenterol 107 2012 28 35 quiz 36
108. M. Pimentel, A. Lembo, W.D. Chey, and et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation N Engl J Med 364 2011 22 32
109. L.B. Weinstock Long-term outcome of rifaximin therapy in non-constipation irritable bowel syndrome Dig Dis Sci 56 2011 3389 3390
110. K. Whelan Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews Curr Opin Clin Nutr Metab Care 14 2011 581 587
111. G.C. Parkes, J. Brostoff, K. Whelan, and J.D. Sanderson Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment Am J Gastroenterol 103 2008 1557 1567
112. J.M. Lackner, J. Jaccard, S.S. Krasner, and et al. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility Clin Gastroenterol Hepatol 6 2008 899 906
113. E. Andersson, B. Ljotsson, F. Smit, and et al. Cost-effectiveness of internet-based cognitive behavior therapy for irritable bowel syndrome: results from a randomized controlled trial BMC Public Health 11 2011 215
114. P. Lindfors, B. Ljotsson, E. Bjornsson, and et al. Patient satisfaction after gut-directed hypnotherapy in irritable bowel syndrome Neurogastroenterol Motil 25 2013 169 e86
115. B. Ljotsson, E. Hedman, E. Andersson, and et al. Internet-delivered exposure-based treatment vs. stress management for irritable bowel syndrome: a randomized trial Am J Gastroenterol 106 2011 1481 1491
116. P.M. Boyce, N.J. Talley, B. Balaam, and et al. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome Am J Gastroenterol 98 2003 2209 2218
117. L.R. Harris, and L. Roberts Treatments for irritable bowel syndrome: patients' attitudes and acceptability BMC Complement Altern Med 8 2008 65
118. A.N. Webb, R.H. Kukuruzovic, A.G. Catto-Smith, and S.M. Sawyer Hypnotherapy for treatment of irritable bowel syndrome Cochrane Database Syst Rev 4 2007 CD005110
119. P. Lindfors, P. Unge, P. Arvidsson, and et al. Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials Am J Gastroenterol 107 2012 276 285
120. O.S. Palsson, and W.E. Whitehead Psychological treatments in functional gastrointestinal disorders: a primer for the gastroenterologist Clin Gastroenterol Hepatol 11 2013 208 216 quiz e22-e23
121. P. Lindfors, P. Unge, H. Nyhlin, and et al. Long-term effects of hypnotherapy in patients with refractory irritable bowel syndrome Scand J Gastroenterol 47 2012 414 420
122. A.C. Ford Acupuncture for irritable bowel syndrome Gastroenterology 143 2012 1683 1684
123. E. Manheimer, L.S. Wieland, K. Cheng, and et al. Acupuncture for irritable bowel syndrome: systematic review and meta-analysis Am J Gastroenterol 107 2012 835 847 quiz 48
124. A.C. Ford, N.J. Talley, B.M. Spiegel, and et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis BMJ 337 2008 a2313
125. R. Rahimi, and M. Abdollahi Herbal medicines for the management of irritable bowel syndrome: a comprehensive review World J Gastroenterol 18 2012 589 600
126. J.P. Liu, M. Yang, Y.X. Liu, and et al. Herbal medicines for treatment of irritable bowel syndrome Cochrane Database Syst Rev 1 2006 CD004116
127. E. Johannesson, M. Simren, H. Strid, and et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial Am J Gastroenterol 106 2011 915 922
128. J.E. Kurlander, and D.A. Drossman Diagnosis and treatment of narcotic bowel syndrome Nat Rev Gastroenterol Hepatol 11 2014 410 418